Structure Therapeutics (GPCR)

Executive Summary

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) for metabolic and pulmonary diseases. Leveraging its proprietary structure-based drug discovery platform integrating cryo-EM, computational modeling, and machine learning, the company aims to address previously intractable GPCR targets. Its lead asset, aleniglipron (formerly GSBR-1290), is an oral GLP-1 receptor agonist in Phase 2 development for obesity and overweight management. Recent Phase 1/2 data demonstrated clinically meaningful weight loss with a favorable safety profile, positioning aleniglipron as a potential best-in-class oral therapy in the rapidly growing obesity market. The company is also advancing GSBR-1290 for type 2 diabetes and exploring earlier-stage pipeline candidates. With a strong cash position and a focus on executing its clinical development plan, Structure Therapeutics is poised to deliver key catalysts in the near term.

Upcoming Catalysts (preview)

• Q4 2026Top-line Phase 2 data from aleniglipron obesity trial (NCT07169942)60% success
• Q3 2026Top-line Phase 2 data from aleniglipron obesity trial (NCT06693843)60% success
• H2 2026Potential partnership or licensing deal for aleniglipron or platform40% success